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Abstract
Chronic kidney disease is a long-term complication in acute intermittent porphyria (AIP). The pathophysiological
significance of hepatic overproduction of the porphyrin precursors aminolevulinate acid (ALA) and porphobilinogen (PBG)
in chronic kidney disease is unclear. We have investigated the effect of repetitive acute attacks on renal function and the
effect of total or five-sixth nephrectomy causing renal insufficiency on hepatic heme synthesis in the porphobilinogen
deaminase (PBGD)-deficient (AIP) mouse. Phenobarbital challenge in the AIP-mice increased urinary porphyrin precursor
excretion. Successive attacks throughout 14 weeks led to minor renal lesions with no impact on renal function. In the liver of
wild type and AIP mice, 5/6 nephrectomy enhanced transcription of the first and rate-limiting ALA synthase. As a
consequence, urinary PBG excretion increased in AIP mice. The PBG/ALA ratio increased from 1 in sham operated AIP
animals to over 5 (males) and over 13 (females) in the 5/6 nephrectomized mice. Total nephrectomy caused a rapid decrease
in PBGD activity without changes in enzyme protein level in the AIP mice but not in the wild type animals. In conclusion,
high concentration of porphyrin precursors had little impact on renal function. However, progressive renal insufficiency
aggravates porphyria attacks and increases the PBG/ALA ratio, which should be considered a warning sign for potentially
life-threatening impairment in AIP patients with signs of renal failure.
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Introduction
Acute intermittent porphyria (AIP, OMIM 176000) is an
inherited metabolic disease characterized by partial deficiency of
hepatic porphobilinogen deaminase (PBGD). The disease is
inherited in an autosomal dominant manner and is the most
common of the acute porphyrias [1]. The dominant clinical
feature is characterized by acute attacks of abdominal pain,
hypertension and neurovisceral and circulatory disturbances, a
condition which if untreated may become life-threatening. An
inherited deficiency of PBGD is not sufficient for the symptoms to
appear. Acute attacks can be induced by various drugs,
nutritional factors and hormonal changes [2]. Drugs metabolized
by CYP450, such as phenobarbital, greatly increase hepatic heme
demand and result in the up-regulation of hepatic aminolevuli-
nate synthase (ALAS1), increasing the production of porphyrin
precursors and precipitating the attack. Advances in medical care
and self-care have improved the prognosis for symptomatic
patients [3]. Still, some patients develop recurrent crises or
progressive disease with disabling neurological dysfunction and/
or renal failure.
Chronic kidney disease may occur as a long-term complication
of symptomatic disease in acute porphyrias, leading to vascular
complications, progression of peripheral neuropathy and eventu-
ally need for dialysis. Chronic arterial hypertension and renal
impairment become more common after middle age in AIP,
especially in patients with frequent porphyric attacks [4,5].
Limited information is available on the characteristics and
pathogenesis of renal disease in this patient group and little is
known about the association between renal damage and acute
porphyrias. The disease may be accompanied by electrolyte
abnormalities. Hyponatremia is common during the acute attack
and may be due to inappropriate secretion of antidiuretic
hormones. The increased urinary excretion of catecholamines
during an acute attack suggests up regulation of the sympathetic
nervous system and may contribute to the etiology of renal
damage. Chronic hypertension in AIP has an estimated incidence
of 36–55% [3]. However, long-term treatment with modern
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32978antihypertensive drugs has minor the repercussion on renal
function.
There are few studies in which biopsies have been performed in
patients with AIP. In one large population study [4], 16 patients
were found with renal impairment with no other cause than AIP.
Nine of the 10 patients that underwent renal biopsy had
hypertension. The biopsies showed varying degrees of nephro-
sclerosis, moderate tubular atrophy and interstitial fibrosis and
vessel wall thickening. Other few authors reported nephrosclerosis
and shrunken kidney more in accordance to hypertension damage
[6,7,8]. Finally, renal biopsy data from patients without hyper-
tension or glomerular lesions but with features of tubulointerstitial
disease suggest an enhanced susceptibility to the nephrotoxic
effects of porphyrin precursors and porphyrins [9,10]. Both types
of damages directly or indirectly may point to active AIP, with or
without frequent hemin administration [11], as an important
factor causing renal disease. Of interest, a selective accumulation
and excretion of PBG has been found in most porphyric patients
with renal failure [9,11] and an increased PBG/ALA ratio was
proposed as a warning sign associated to changes in the renal
filtration.
In the present work, using an AIP mouse model [12], we studied
the effects on renal function of repetitive acute attacks, as well as
the effects of partial or total nephrectomy causing renal
insufficiency. This report is the first in vivo study to address the
liver-kidney interaction during acute porphyric attacks. Although
the mouse is a predictive model for AIP, extrapolation to human
disease is considered and discussed in the paper.
Results
Successive induced biochemical attacks increased
porphyrin precursor accumulation with no impact on
renal function
The AIP mouse model exhibits a 70% loss of PBGD activity in
the liver and replicates the drug-precipitated biochemical
abnormalities of acute porphyria in humans [12]. The adminis-
tration of four consecutive intraperitoneal daily doses of
phenobarbital massively increased urinary excretion of heme
precursors and decreased motor function. Histopathological
findings include axonal neuropathy and decrease nerve conduc-
tion with aging [12][13]. In order to study the nephrotoxic effects
of porphyrin precursors and porphyrins, seven successive attacks
over 14 weeks were induced in one year old male AIP mice.
Matched wild type mice were used as controls. As expected,
phenobarbital challenge increased urine levels of ALA, PBG
(Figure 1A) and porphyrins (Figure 1B) in AIP mice. The mean
excretion of PBG (mg per mg creatinine) was twice as high as the
excretion of ALA (Figure 1A), i.e. PBG/ALA ratio 2. The daily
amount of PBG and ALA excreted in the urine after the 7
th
phenobarbital challenge was significantly higher than that after the
3
rd challenge. Urinary porphyrin precursors and porphyrins were
unchanged within the normal range in wild type animals
(Figure 1A, 1B). In AIP mice, successive acute attacks did not
modify renal function as measured by blood urea nitrogen values
(Figure 1C).
These animals were sacrificed three days after the last
phenobarbital dose of a challenge. The ALAS1 mRNA level was
significantly increased in AIP mice when compared with wild type
mice, 2.361.2 vs 1.060.9 Arbitrary Units, respectively; p=0,0498,
one-tailed unpaired t-test with Welch’s correction.
Histological analysis of kidney tissues from AIP mice and age-
matched wild type animals showed lack of porphyrin deposits and
no vascular or tubulointerstitial damage (Figure 1C). Half of the
animals from each group exhibited focal accumulations of
mononuclear inflammatory cells, mostly in the perivascular space.
Light micrographs of kidney sections showed relatively innocuous
tubular dilatation in one AIP animal (Figure 1D) and diffuse
cortical atrophy in the subcapsular region in another AIP animal
(Figure 1E). These changes had no impact on renal function and
can occur as a senile change in old wild type animals. These results
show that high excretion of porphyrin precursors and porphyrins
have little impact on renal function. Mild degrees of renal lesions
can occur as a senile change in old animals and seem unrelated to
acute attacks of porphyria.
Partial nephrectomy raised urinary PBG/ALA ratio in
porphyric animals
In a second study, five-sixth nephrectomy was performed in
adult wild type and AIP mice after 2/3 nephrectomy of one kidney
and extirpation of the other. Other cohorts of mice were sham-
operated. Heme precursor excretion were measured before and
after phenobarbital challenge (Figure 2A–C and Table 1). Renal
insufficiency caused by 5/6 nephrectomy per se increased in the
AIP mice the urinary PBG excretion (Figure 2A, baseline) in male
and female, p=0.008 and p=0.007 respectively, compared to
values in sham operated AIP mice. No changes were observed in
urinary ALA (Figure 2B, baseline) and porphyrin excretion
(Table 1). As expected, phenobarbital challenge exacerbated
ALAS1 up-regulation and high levels of both porphyrin precursors
and porphyrins were found in the urine (Figure 2A and 2B and
Table 1), both in sham operated and 5/6 nephrectomized AIP
mice of both sexes.
Phenobarbital challenge underlined the selective accumulation
of PBG in partially nephrectomized animals, as measured by the
increased PBG/ALA ratio (Figure 2C). The urinary PBG/ALA
ratio in wild type and AIP mice with conserved renal function was
under 1.0. In the 5/6 nephrectomized AIP mice, the PBG/ALA
ratio increased above 1.0, and phenobarbital challenges further
increased this ratio from 1 to 5 in males (Figure 2C, left) and from
5 to 13 in AIP females (Figure 2C, right). Of note, five-sixth
nephrectomy did not result in porphyrin accumulation in the
serum (Table 1), suggesting that porphyrins were readily filtered by
the remnant kidney. The increased concentration of urinary
porphyrin observed in sham operated and nephrectomized AIP
mice after phenobarbital challenge, is a consequence of nonenzy-
matic condensation of PBG to uroporphyrin I [14].
The genetic expression and activity of the three first enzymatic
steps of the heme synthesis pathway was assessed in the liver of
these nephrectomized mice 24 h after the last phenobarbital dose
are shown in Figure 3 (female) and Figure 4 (male). The 5/6
nephrectomy increased ALAS1 mRNA levels (Figure 3A and 4A)
and reduced ALA dehydratase (ALAD) activity in the liver
(Figure 3B and 4B) in both wild type and AIP mice. As there were
significant sex differences in hepatic ALAS1 mRNA levels and
ALAD activity the results are presented separately.
No changes were found in the activity of the PBGD enzyme in
wild type animals (Figure 3C and 4C). The genetically deficient
PBGD activity was not further decreased by 5/6 nephrectomy
(Figure 3C and 4C). The mRNA levels for ALAD and PBGD
found in the liver substantiated the respective hepatic enzyme
activity obtained in these animals (Figure S1). These data
suggested that ALAS1 over-expression induced by partial
nephrectomy, increases the synthesis of heme precursors, causing
a selective accumulation of PBG, the substrate of the deficient
enzyme, PBGD. ALA was not increased and suggested that ALAD
can not became a rate-limiting step even after a marked decrease
subsequent to partial nephrectomy.
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32978Figure 1. Lack of glomerular, tubulointerstitial or vascular damage in acute intermittent porphyria mice after sustained urinary
porphyrin precursors and porphyrin excretion induced by phenobarbital challenge. The effect of repetitive acute attacks on renal
function was assayed in four AIP male mice aged from 9 to 14 months. Seven consecutive phenobarbital challenges were administered at intervals of
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32978In male animals, sham-operated AIP mice showed 3-fold
increased ALAS1 mRNA levels when compared with wild type
animals (Figure 4A). These data (obtained from animals sacrificed
three days after last phenobarbital dose) suggested that transcrip-
tional activation of the hepatic ALAS1 gene in response to
xenobiotic challenge in the AIP mice remained active over a
longer time in males compared to females. Differences in the
duration of ALAS1 activation during phenobarbital challenge
correlates with the higher excretion of porphyrin precursors in
males compared to females (Figure 2). However, 5/6 nephrectomy
exacerbated a selective accumulation of PBG in both females
(from 5 before to 13 after 5/6Nx) and males (from 1 before to 5
after 5/6Nx) (Figure 2C).
The remnant kidney pole from AIP mice illustrated normal
glomerular architecture without vascular atrophy or heme
precursor deposits (Figure S2). Histology also showed lack of
tubulointerstitial damage and inflammatory cell infiltrate. These
data suggested that the presumably noxious effect of porphyrin
precursors and porphyrins on renal parenchyma were not
intensified after reduction of renal function in the AIP mice
model during the observation time.
Total nephrectomy induced a rapid decrease in PBGD
activity in AIP mice
In order to measure the impact of terminal renal disease on the
hepatic heme synthesis pathway, a total nephrectomy was
performed in another cohort of mice during a phenobarbital
challenge. Lack of renal function produced a rapid accumulation
of heme precursors in serum of the AIP mice (Table 1). Ten hours
after nephrectomy, hepatic transcription levels of ALAS1 were
found to be unchanged in both female (Figure 3A) and male AIP
mice (Figure 4A) when compared with sex-matched wild type
animals. Of interest, a rapid decrease in hepatic PBGD activity
was observed exclusively in AIP mice (Figure 3C and 4C), with no
changes in transcriptional activity (Figure S1) or enzyme protein
level (Figure S3). It may be assumed that the observed aggravation
of PBGD deficiency may be a consequence of further PBGD-
inhibition caused by the large substrate accumulation caused by
impaired glomerular filtration.
Discussion
Limited information is available on the association between
acute intermittent porphyria and kidney failure. The development
of end stage renal disease is a devastating complication in AIP
patients with chronic active disease, leading to unavoidable
vascular complications, dialysis treatment, progression of periph-
eral motor neuropathy and, occasionally, respiratory failure [15].
Such patients may also suffer from cutaneous bullous lesions
resembling PCT [11,16]. Current treatment of acute attacks
involving intravenous administration of hemin and a high-
carbohydrate diet only has a transitory effect and cannot prevent
accumulation of porphyrin precursors and porphyrins in-between
cures [11]. There are no reports of longstanding follow-up of renal
function in patients afflicted by recurrent acute attacks and only
few studies have reported results of kidney biopsies in AIP patients
with chronic disease [4,9,10].
The leading hypothesis is that the porphyric state may
progressively damage the kidneys sufficiently to cause renal failure.
It has been suggested that the presence of excessive amounts of
porphyrin precursors and porphyrins causes cytotoxic or vaso-
spastic renal vascular lesions leading to glomerulonephritis and
tubulointerstitial nephritis [9,10,11]. Repeated hemin therapy may
also contribute to renal damage [17,18]. The high accumulation of
porphyrin precursors, mainly ALA, has been proposed as a cause
of renal toxicity by oxidative stress and lipid peroxidation in
microsomal and mitochondrial membranes [10,19]. ALA accu-
mulation is thought to be related to increased oxidative stress [20].
However, increased incidence of primary liver cancer in Swedish
and French patients suffering from AIP [21,22,23] has not directly
pointed to a correlation between disease activity and increased
levels of porphyrin precursors, i.e. oxidative stress. Moreover,
there is no evidence of a high incidence of renal cancer in AIP
patients, at least not in the Swedish and Danish cohorts [21].
In our in vivo model, acute attacks were periodically induced by
phenobarbital challenge causing intermittent accumulation of
porphyrin precursors and porphyrins over a period of 3 months
failed to show any important impact on renal function and
histology. Probably the toxic effects of porphyrin precursors and
porphyrins on the kidney need extended periods of time to
significantly alter renal physiology, as occurs in a small number of
patients who develop chronic AIP disease characterized by a
relatively constant high excretion of porphyrin precursors
throughout years [11,24]. However, most of the AIP-patients
with frequent acute attacks do not develop end stage renal disease,
which suggests that other key factors are involved [25].
Partial nephrectomy induced the hepatic ALAS1 in both wild
type and AIP mice. The up-regulated heme biosynthesis in the
AIP mice with genetically deficient PBGD activity gave rise to a
selective accumulation of PBG after phenobarbital challenges,
leading to an increase in the urinary PBG/ALA ratio. The
increased PBG/ALA ratio could not be related to decreases in
glomerular filtration since the excretion of molecules such as
porphyrins, were not impaired by 5/6 nephrectomy. Thus our
data demonstrate that renal insufficiency exacerbated the acute
porphyric state shown biochemically by the selective accumulation
of PBG, the substrate of the deficient enzyme PBGD. Thus, under
conditions of ALAS1 up-regulation, as after 5/6 nephrectomy, the
already deficient PBGD enzyme in the liver of the AIP mice may
become further overloaded. In the few cases reported by Miyagi et
al. [26], PBGD activity measured in the liver of seriously afflicted
AIP patients was found to be very low or undetectable. i.e. not the
expected 50% of normal activity described for human AIP. The
decreased activity was related to a marked increase in serum PBG,
suggesting that the PBG might cause further inhibition of hepatic
PBGD.
This hypothesis may be supported by this in vivo study using the
AIP mouse model. Heme biosynthesis induced by phenobarbital
administration was followed by total nephrectomy i.e. abolishment
of glomerular filtration of heme precursors. Ten hours after total
two weeks in order to maintain high hepatic production and high flow of both porphyrin precursors and porphyrin throughout the kidney. Four age-
matched wild type male animals were used as controls. After the fourth consecutive dose of each phenobarbital challenge AIP mice developed a
biochemical attack, characterized by A) high levels of urinary porphyrin precursors and B) porphyrin accumulation. C) Blood urea nitrogen (BUN) and
individual pathological analysis of kidney necropsies. Histological analysis was performed in renal samples taken three days after the last
phenobarbital challenge. Prognostic scores in histological analysis of renal biopsies were analysed by a trained pathologist (ES) as described in
Methods. D) Light micrographs of kidney sections showed relatively innocuous tubular dilatation in one AIP animal. Another AIP animal showed
diffuse cortical atrophy E), which was more prominent in the subcapsular region. Magnification6200. The Wilcoxon matched pairs test was used for
comparison. The null hypothesis was rejected when p#0.05. WT, wild type; AIP, Acute Intermittent Porphyria.
doi:10.1371/journal.pone.0032978.g001
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32978nephrectomy there was an important inhibition of the already
decreased hepatic PBGD activity (but not the protein enzyme).
These studies demonstrate that end stage renal insufficiency may
aggravate the acute porphyria state, hypothetically by substrate
inhibition. Physiologically, in a post-translational step, a dipyrro-
methane cofactor is assembled to apo-PBGD to become the
holoenzyme PBGD [27]. An excess of PBG may alter this process
and prevent the formation of active PBGD holoenzyme causing a
further drop in PBGD activity [28].
The reduced hepatic ALAD activity associated with renal
impairment did not modify ALA accumulation as suggested by
unchanged urinary ALA excretions in the AIP mice. In fact, the
inhibition of ALAD is only significant for ALA accumulation when
important ALAD deficiency is observed. This is the case of the
homozygous patients with ALAD deficiency, lead poisoning and
hereditary tyrosinemia deficiency where the hepatic ALAD
activity is less than 1% of the reported normal activity [29,30].
In conclusion, consecutive phenobarbital challenge in mice
caused slight degrees of renal lesions unrelated to porphyria and
indicated that massive porphyrin or porphyrin precursor excre-
tion, or their passage through the kidney, did not modify renal
function in AIP mice. However, conclusions obtained in the AIP
mouse model cannot be extrapolated to chronic AIP disease and
we cannot disregard the potential deleterious effect of high
porphyrin and porphyrin precursor accumulation maintained
during years. Indeed, once end stage renal disease was established
we cannot rule out the deleterious effect of porphyrin accumula-
tion since dialysis membranes display a limit efficiency to filter
these molecules [11].
Our results indicate that progressive renal insufficiency in AIP
mice may aggravate the acute porphyria state. These data may
illustrate the pathophysiology in AIP patients afflicted by recurrent
acute attacks and renal failure. This is an extremely vulnerable
clinical condition in which the development of severe neuropathic
complications is very likely. Even though dialysis membranes are
able to clear porphyrin precursors [6,11,31,32], ALA and PBG
accumulate during the inter-dialysis period and may be respon-
sible for the progression of nerve damage. Increased PBG is
nonenzymatically polymerized to uroporphyrin I, a molecule that
is not cleared by dialysis leading to accumulation of serum
porphyrins and consequently to photosensitivity skin damage [11].
The increase in PBG/ALA ratio should be considered a
warning sign for potentially life-threatening aggravation of the
porphyric condition. These patients should be candidates for
combined kidney and liver transplantation, in order to correct the
primary enzyme deficiency as well as restore renal function. These
data and other recent cases have clarified previous concerns and
could help to formulate the indications for and the timing of
transplantation in AIP.
Materials and Methods
Animal studies. Experimental protocols were performed ac-
cording to European Council Guidelines. Acceptable standards of
Figure 2. Porphyrin precursor excretion in wild type and AIP mice suffering from different degrees of renal insufficiency. The effect
of five-sixth nephrectomy on urine excretion of aminolevulinate acid (ALA) and porphobilinogen (PBG) was compared with respect to urinary
excretion in sham-operated mice. Urine levels of ALA and PBG were also measured in these animals after phenobarbital challenge that induces a
biochemical attack of porphyria specifically in AIP mice. A) Urinary PBG excretion. B) Urinary ALA excretion. C) Urinary PBG/ALA ratio. The non-
parametric Mann–Whitney U-test was used for comparison of two groups. Nx5/6, 2/3 nephrectomy of the left kidney and extirpation of the right
kidney. The null hypothesis was rejected when p#0.05. WT, wild type; AIP, Acute Intermittent Porphyria.
doi:10.1371/journal.pone.0032978.g002
Table 1. Serum cystatine and porphyrin levels in wild type and AIP mice with different degrees of chronic renal failure.
Parameter Group
Phenobarbital
administration WT male AIP male WT female AIP female
Serum cystatine (ng/ml) Sham - 337 6 73 297 6 134 291 6 129 276 6 128
Nx 2/6 - 445 6 112 560 6 58 * 424 6 132 * 537 6 26 *
Nx 5/6 - 2164 6 791 * 1157 6 982 * 2075 6 1050 * 1870 6 1075 *
Nx 6/6 - 3494 6 570 * 3864 6 687 * 3004 6 656 * 3683 6 731 *
Serum porphyrines (nmol/l) Sham No 3.0 6 0.7 3.6 6 0.7 2.7 6 0.5 3.4 6 0.5
Sham Yes 3.2 6 0.5 6.6 6 2.6 3.3 6 1.1 7.6 6 2.4 *
Nx 5/6 Yes 7.4 6 2.4 9.5 6 2.8 * 5.9 6 3.7 16.8 6 18.7 *
Nx 6/6 Yes 10.9 6 6.2 62 6 41 * 8.7 6 3.8 20.4 6 8.5 **
Hepatic porphyrines (nmol/g
prot.)
Sham No 0.6 6 0.1 2.5 6 0.5 0.7 6 0.8 2.2 6 0.5
Sham Yes 1.0 6 0.1 2.9 6 0.3 0.8 6 0.3 2.2 6 0.04
Nx 5/6 Yes 0.5 6 0.2 1.6 6 1.0 0.7 6 0.3 2.8 6 1.35
Nx 6/6 Yes 0.9 6 0.2 2.9 6 0.4 1.0 6 0.4 2.4 6 0.3
Urine porphyrines (nmol/l) Sham No 23 6 73 9 6 81 5 6 43 8 6 16
Sham Yes 16 6 93 4 4 6 141 ** 33 6 18 154 6 90 *
Nx 5/6 No 20 6 33 7 6 27 40 6 64 8 6 8
Nx 6/6 Yes 8 6 21 9 6 6 95 ** 39 6 56 203 6 147 *
WT, wild type; AIP, Acute Intermittent Porphyria, Nx5/6, 2/3 nephrectomy of the left kidney and extirpation of the right kidney; Nx 6/6, total nephrectomy. Mann–
Whitney U-test was used for comparison of two groups (* P,0.05, ** P,0.01 vs Sham-operated group with no phenobarbital administration). The null hypothesis was
rejected when P#0.05.
doi:10.1371/journal.pone.0032978.t001
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32978Figure 3. Expression profile of hepatic ALAS, ALAD and PBGD
in female wild type and AIP mice suffering from different
degrees of renal insufficiency. A group of 4 wild type and 9 AIP
female mice were subjected to 5/6 nephrectomy (5/6 Nx) while
complete bilateral nephrectomy was performed in 6 wild type and 7 AIP
mice. A group of 5 wild type and 6 AIP female animals were sham-
operated. A) Quantitative real-time PCR analysis of ALAS mRNA from
liver samples. The amount of each transcript was expressed according
to the formula 2
DCt(Actin)2DCt(gene), where DCt is the point at which the
fluorescence rises appreciably above background fluorescence. B) ALAD
and C) PBGD activities measured in the liver of mice taken at sacrifice.
The non-parametric Mann–Whitney U-test was used for comparison of
two groups. Nx5/6, 2/3 nephrectomy of the left kidney and extirpation
of the right kidney; Nx 6/6, total nephrectomy. ALAS, hepatic
aminolevulinate acid synthase; ALAD, aminolevulinate acid dehydra-
tase; AIP, Acute Intermittent Porphyria.
doi:10.1371/journal.pone.0032978.g003
Figure 4. Expression profile of hepatic ALAS, ALAD and PBGD
in male wild type and AIP mice suffering from different
degrees of renal insufficiency. A group of 5 wild type and 8 AIP
male animals were subjected to 5/6 nephrectomy (5/6 Nx) while
complete bilateral nephrectomy was performed in 4 wild type and 6 AIP
mice. A group of 6 wild type and 8 AIP male animals were sham-
operated. A) Quantitative real-time PCR analysis of ALAS mRNA, B)
enzyme ALAD and C) PBGD activities measured in the liver of wild type
and AIP male animals. The non-parametric Mann–Whitney U-test was
used for comparison of two groups. Nx5/6, 2/3 nephrectomy of the left
kidney and extirpation of the right kidney; Nx 6/6, total nephrectomy.
ALAS, hepatic aminolevulinate acid synthase; ALAD, aminolevulinate
acid dehydratase; AIP, Acute Intermittent Porphyria.
doi:10.1371/journal.pone.0032978.g004
Renal Failure Exacerbates Porphyria Attacks
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32978humane animal care and treatment employed in these mice (ref.
no. CEEA022-06) and the experimental design of this study (ref.
no. CEEA029-09) were approved by the Ethics Committee for
Animal Testing of the University of Navarra. AIP mice [12] are
compound heterozygotes of two different disruptions of the PBGD
gene: T1 (C57BL/6-pbgd
tm1(neo)Uam) and T2 strain (C57BL/6-
pbgd
tm2(neo)Uam) mutations. To biochemically imitate a human
porphyria attack, AIP mice were injected intraperitoneally with
increasing doses of phenobarbital (75, 80, 85, 90 mg/kg body
weight) for four consecutive days (i.e. phenobarbital challenge).
Urines (24-hour) were collected in metabolic cages.
Partial or total nephrectomies were performed in 4- to 6-month
old mice of both sexes. Acute renal failure was induced surgically.
Mice were anaesthetized and kidneys were exposed by dorsal flank
incision. In the 5/6 nephrectomy model, the renal artery was
briefly clamped and two thirds of the left kidney (upper and lower
poles) were excised, leaving the upper pole renal capsule and
adrenal gland intact. One week later, the right kidney was
removed after ligation of the renal artery, vein and ureter. A
phenobarbital challenge was administered one month after
extirpation of the right kidney. One day after the last
phenobarbital injection, 24-hour urine and serum samples were
collected, animals were sacrificed, and the three first enzymatic
steps in hepatic heme biosynthesis were investigated.
In the bilateral nephrectomy groups, both kidneys were
removed in the same operation, after ligation of the renal artery,
vein and ureters. The nephrectomy was performed after the last
dose of phenobarbital challenge and animals were killed 10 hours
later. Serum and liver samples were collected at each time.
Biochemical analysis. Renal impairment was estimated by
serum blood urea nitrogen levels (Ref. 11489364 216, Roche,
Germany) or serum cystatin C concentration (Mouse Cystatin C
ELISA, BioVendor GmbH) [33] in nephrectomized animal. Total
porphyrins were extracted from serum and liver samples with
1 mol/L HCLO4/CH3OH (1:1, vol/vol) and measured in a
Spectrofluorometer (LS50B, PerkinElmer, Madrid, Spain). Uri-
nary porphyrin concentration was measured according to
Westerlund et al. [34]. Uroporphyrin I solutions (10 nmol/L)
were used as a standard. Porphyrin precursors, PBG and ALA,
were quantified in 24 h urine samples using a quantitative ion
exchange column method (BioSystems SA, Barcelona, Spain) and
measured by spectrophotometry (Ultrospc 3000, Pharmacia
Biotech, Buckinghamshire, UK) at 555 nm. The hepatic activity
of aminolevulinate dehydratase was determined by spectropho-
tometry [35]. PBGD activity was measured as described [13].
RNA extraction and hepatic liver enzyme expression analysis.
Total RNA was extracted from liver tissues using TRIzol Reagent
(Invitrogen life technologies). Total RNA was used to make cDNA
using the Stratascript first strand cDNA synthesis kit (Stratagene).
The steady state mRNA level of the ALAS1 was analyzed by
quantitative RT-PCR using iQ SYBR green supermix in an iQ5
real-time PCR detection system (Bio-Rad, Hercules, CA). PCR
amplification was performed under the following conditions: one
cycle of 3 min. at 95uC; followed by 35 cycles of 15 s at 95uC, 30 s
at 60uC, 25 s at 72uC, and 10 s at 70uC, 10 s at 75uC and 30 s at
80uC (detection temperature of 82uC); followed by a single final
extension cycle of 72uC for 4 min. Relative transcript level was
determined using primers annealing specific cDNA sequences of
ALAS1 (forward primer: 59-CAAAGAAACCCCTCCAGCCAA -
39, reverse primer: 59-GCTGTGTGCCGTCTGGAGTCTGTG
-39, product length:101 bp). The amount of ALAS1 transcript was
calculated as the n-fold difference relative to the control gene actin
as an internal control (forward primer: 59-CGCGTCCACCCGC-
GAG -39, reverse primer: 59-CCTGGTGCCTAGGGCG -39,
product length: 193 bp). Results were expressed according to the
formula 2
DCt(Actin)2DCt(gene), where DCt represents the difference in
threshold cycle between the target and control genes.
Histology and histochemical staining. Formalin-fixed paraffin
embedded sections (5 mm) of right and left kidneys were processed
for hematoxylin and eosin and sirius red stainings. Lesions and
prognostic score of renal biopsies were evaluated by a trained
pathologist (ES) using a semiquantitative score adapted from the
Banff’s consensus criteria for the evaluation of renal allograft
biopsies (doi: 10.1111/j.1600-6143.2006.01688.x). Briefly, glo-
merular, tubulointerstitial and vascular lesions were scored
(0=absence; 1=mild; 2=moderate; 3=severe). The main
features scored were: chronic glomerulopathy, tubulitis (t), tubular
atrophy (a), interstitial inflammation (i), interstitial fibrosis (sirius
red positive) (f), vasculitis (v), subendothelial thickening (th), and
arteriolar hyalinosis (ah). In addition, presence of crystals or
deposits was ascertained, and occasional findings were reported
under ‘observations’.
Supporting Information
Figure S1 Expression levels of ALAD and PBGD in the
liver of AIP mice suffering from different degrees of
renal insufficiency. The cDNA samples were obtained as
described in Materials and Methods section. Quantitative real-
time PCR were performed using primers annealing specific cDNA
sequences of ALAD (forward primer: 59-ACGTCTGCTTGT-
GCCCCTAC -39, reverse primer: 59-ACAGCGTCGGTCTC-
CAAAAG -39, product length: 311 bp) or PBGD (forward primer:
59-CACTGCCCGTAACATTCCAA -39, reverse primer: 59-
GCAACATCCAGGATGTTCTTG -39, product length: 107 bp).
The amount of each transcript was calculated as the n-fold
difference relative to the control gene actin as an internal control
(forward primer: 59-CGCGTCCACCCGCGAG -39, reverse
primer: 59-CCTGGTGCCTAGGGCG -39, product length:
193 bp). The amount of each transcript was expressed according
to the formula 2
DCt(Actin)2DCt(gene), where DCt represents the
difference in threshold cycle between the target and control genes.
The non-parametric Mann–Whitney U-test was used for compar-
ison of two groups of mice. Nx5/6, 2/3 nephrectomy of the left
kidney and extirpation of the right kidney; Nx 6/6, total
nephrectomy. ALAD, aminolevulinate acid dehydratase; PBGD,
porphobilinogen deaminase; AIP, Acute Intermittent Porphyria.
(TIF)
Figure S2 Lack of histological abnormalities in the
remnant kidney pole from porphyric mice one month
after 2/3 nephrectomy of the left kidney and extirpation
of the right kidney. A) This image indicates well organized
histoarchitecture of the renal cortex from a porphyric mice.
Glomerulus (arrow) was surrounded by glomerular capsule
including proximal (*) and distal tubules (#), B) Cross sections of
tubules in the medulla. Kidney samples were taken three days after
the last phenobarbital dose. No heme precursor deposits or
vascular atrophy were observed (periodic acid-Schiff stain,
magnification 6200).
(TIF)
Figure S3 Unchanged hepatic PBGD protein level in
wild type and AIP mice ten hours after total nephrecto-
my. Male mice data are presented in left panel and female
animals in the right panel. Immunoblot assay was performed as
described [13]. Briefly, total liver proteins (50 mg/lane) were
resolved by electrophoresis on a 12% polyacrylamide gel and
blotted onto PVDF membranes (Amersham HybondTM-P,
Renal Failure Exacerbates Porphyria Attacks
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e32978Buckimghamshire.UK). After blocking, the membranes were
incubated with primary antibodies against human PBGD
(1:5000, rabbit polyclonal anti-hPBGD) or GAPDH antibodies
(1:5000, AbD SEROTEC, Oxford. UK). Secondary antibodies
used were anti- rabbit (1:5000, GAR, Biorad) or anti mouse
(1:5000, GAM, Pierce-Rockford. IL), respectively. The signals
were then visualized using the Western Lightning Chemilumines-
cence Reagent Plus (PerkinElmer LAS, Boston). Immunoblot
analysis of hepatic PBGD. Densitometry quantifications were
performed for two independent immunoblots. The non-paramet-
ric Mann–Whitney U-test was used for comparison of two groups
of mice. PBGD, porphobilinogen deaminase; AIP, Acute Inter-
mittent Porphyria.
(TIF)
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